FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Oosthuizen Johannes Jacobus		 2. Issuer Name and Ticker or Trading Symbol

Merck & Co., Inc. [ MRK ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President, U.S. Market
(Last)          (First)          (Middle)

MERCK & CO., INC., 126 LINCOLN AVENUE		 3. Date of Earliest Transaction (MM/DD/YYYY)

11/7/2022
(Street)

RAHWAY, NJ 07065
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/7/2022  M  14703 A$0 26046.881 D  
Common Stock 11/7/2022  M  17455 A$0 43501.881 D  
Common Stock 11/7/2022  M  13540 A$0 57041.881 D  
Common Stock 11/7/2022  M  7045 A$0 64086.881 D  
Common Stock 11/7/2022  S  45561 D$99.4706 (1)18525.881 (2)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $62.07 11/7/2022  M     14703  5/5/2018 (3)5/4/2027 Common Stock 14703 $0 0 D  
Stock Option (Right to Buy) $77.62 11/7/2022  M     17455  5/3/2020 (4)5/2/2029 Common Stock 17455 $0 0 D  
Stock Option (Right to Buy) $75.36 11/7/2022  M     13540  5/1/2021 (5)4/30/2030 Common Stock 13540 $0 6773 D  
Stock Option (Right to Buy) $73.73 11/7/2022  M     7045  5/4/2022 (6)5/3/2031 Common Stock 7045 $0 14094 D  
Explanation of Responses:
(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3700 to $99.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
(2) Holdings include shares acquired in dividend reinvestment transactions.
(3) The options became exercisable in three equal installments on 5/5/2018, 5/5/2019, and 5/5/2020.
(4) The options became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
(5) The options become exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
(6) The options become exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Oosthuizen Johannes Jacobus
MERCK & CO., INC.
126 LINCOLN AVENUE
RAHWAY, NJ 07065

President, U.S. Market
Signatures
/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen11/7/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.